Division of Bristol-Myers Squibb Co.
Latest From IFM Therapeutics
The Swiss major has bought a US biotech that specializes in targeting the NLRP3 pathway in a deal valued at up to $1.58bn.
With $46m funding fresh in its pocket, Dublin biotech Inflazome tells Scrip how it will advance its clinical candidates in multiple indications.
Private Company Edition: Gossamer, Ascentage and Alector continued the trend of large venture capital rounds, recently raising $230m, $150m and $133m, respectively. Led by former Receptos executives, Gossamer has multiple clinical trials planned, but continues to keep details of its drug candidates under wraps.
Execs from Merck, Pfizer, Bristol, Abbvie and smaller biopharmas weigh in on how developments in cancer research may benefit other disease areas, especially autoimmune and neurological conditions.
- Therapeutic Areas
- North America
- Company Type
- Parent & Subsidiaries
- Bristol-Myers Squibb Co.
- Senior Management
Gary D Glick, PhD, CEO
Shomir Ghosh, PhD, CSO
Jim Hampe, SVP, Bus. Dev, Operations, & Strategy
- Contact Info
Phone: (781) 267-4858
855 Boylston St.
Boston, MA 02116
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.